Weekly metabolic injections must yield to monthly and long-acting clinical alternatives.
To solve chronic patient non-adherence and escape competitive weekly pricing pressure, the obesity market is rapidly shifting toward monthly injectables and semi-annual subdermal implants.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
Amgen is positioning MariTide as a major competitor to weekly options by advancing monthly and quarterly maintenance dosing regimens in its MARITIME trials.
Pfizer's monthly berobenatide directly challenges standard weekly obesity injection regimens by proving efficacy on a less frequent monthly maintenance schedule.
Viking Therapeutics is proactively clinical-testing biweekly and monthly maintenance regimens to help patients pivot away from weekly injections.
It highlights the clinical shift toward ultra-long-acting once-monthly dosing options to bypass the adherence challenges and pricing pressures of weekly injections.
Novo Nordisk is pursuing a subdermal implant delivering semaglutide for up to a year to bypass weekly injections and solve long-term patient non-adherence.